Organization · Venture Capital
NewVale Capital
NewVale Capital is a Boulder-based growth equity investment firm that focuses on the services architecture of the life sciences industry, investing in proven, revenue-generating businesses that support pharmaceutical and biotechnology companies.
Overview
What NewVale Capital does
What NewVale Capital is
NewVale Capital is a Boulder-based growth equity investment firm that focuses on the services architecture of the life sciences industry, investing in proven, revenue-generating businesses that support pharmaceutical and biotechnology companies.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2022
- Approximate age
- About 4 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find NewVale Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
NewVale Capital as a funder
Investment thesis
NewVale invests exclusively in the life-sciences services architecture: the outsourced services, software, and enabling technologies that pharmaceutical and biotechnology companies rely on to discover, develop, manufacture, validate, and commercialize therapies.
Focus narrative
NewVale Capital focuses on the services architecture of life sciences, specifically targeting businesses involved in the development and delivery of next-generation medicines. The firm seeks to invest in revenue-generating companies that provide critical services and technologies to pharmaceutical and biotech customers, enhancing their ability to discover, develop, and commercialize therapies.
Value beyond capital
NewVale Capital adds value to its portfolio companies by providing not only growth capital but also operational support and sector-specific expertise. The firm leverages its network and experience in the life sciences sector to help companies refine their go-to-market strategies, build operational infrastructure, and enhance supply chain reliability.
Terms and economics
- Typical check
- $10,000,000–$50,000,000
Focus and fit
- Stages
- Growth Equity
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
Aizon: GxP-compliant, AI-enabled software platform for pharmaceutical manufacturing, with a recent USD 20 million growth financing led by NewVale. Argonaut Manufacturing Services: Specializes in aseptic drug-product fill/finish for biopharmaceutical companies, with a USD 45 million financing led by NewVale to expand capacity. Beaconcure: AI-enabled clinical data validation platform for pharmaceutical companies and CROs, supported by a USD 14 million growth financing from NewVale. Noxilizer: Provides proprietary nitrogen dioxide-based sterilization technology for the pharmaceutical and medical device industries, with a USD 30 million growth financing led by NewVale.
Common questions
What to know about NewVale Capital
Upseed classifies NewVale Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.